vs
Side-by-side financial comparison of HAEMONETICS CORP (HAE) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
HAEMONETICS CORP is the larger business by last-quarter revenue ($339.0M vs $194.8M, roughly 1.7× TOMPKINS FINANCIAL CORP). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs 13.2%, a 36.2% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs -2.7%). HAEMONETICS CORP produced more free cash flow last quarter ($87.2M vs $31.9M). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs 0.4%).
Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
HAE vs TMP — Head-to-Head
Income Statement — Q3 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $339.0M | $194.8M |
| Net Profit | $44.7M | $96.2M |
| Gross Margin | 59.7% | — |
| Operating Margin | 19.9% | 71.7% |
| Net Margin | 13.2% | 49.4% |
| Revenue YoY | -2.7% | 152.7% |
| Net Profit YoY | 19.3% | 388.9% |
| EPS (diluted) | $0.95 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $339.0M | $194.8M | ||
| Q3 25 | $327.3M | $87.4M | ||
| Q2 25 | $321.4M | $82.6M | ||
| Q1 25 | $330.6M | $81.7M | ||
| Q4 24 | $348.5M | $77.1M | ||
| Q3 24 | $345.5M | $76.6M | ||
| Q2 24 | $336.2M | $72.7M | ||
| Q1 24 | — | $72.8M |
| Q4 25 | $44.7M | $96.2M | ||
| Q3 25 | $38.7M | $23.7M | ||
| Q2 25 | $34.0M | $21.5M | ||
| Q1 25 | $58.0M | $19.7M | ||
| Q4 24 | $37.5M | $19.7M | ||
| Q3 24 | $33.8M | $18.6M | ||
| Q2 24 | $38.4M | $15.7M | ||
| Q1 24 | — | $16.9M |
| Q4 25 | 59.7% | — | ||
| Q3 25 | 59.5% | — | ||
| Q2 25 | 59.8% | — | ||
| Q1 25 | 58.4% | — | ||
| Q4 24 | 55.5% | — | ||
| Q3 24 | 54.2% | — | ||
| Q2 24 | 52.0% | — | ||
| Q1 24 | — | — |
| Q4 25 | 19.9% | 71.7% | ||
| Q3 25 | 17.9% | 35.6% | ||
| Q2 25 | 16.8% | 34.2% | ||
| Q1 25 | 21.6% | 31.6% | ||
| Q4 24 | 16.9% | 33.4% | ||
| Q3 24 | 15.0% | 32.0% | ||
| Q2 24 | 11.8% | 28.3% | ||
| Q1 24 | — | 30.4% |
| Q4 25 | 13.2% | 49.4% | ||
| Q3 25 | 11.8% | 27.1% | ||
| Q2 25 | 10.6% | 26.0% | ||
| Q1 25 | 17.5% | 24.1% | ||
| Q4 24 | 10.8% | 25.5% | ||
| Q3 24 | 9.8% | 24.3% | ||
| Q2 24 | 11.4% | 21.6% | ||
| Q1 24 | — | 23.2% |
| Q4 25 | $0.95 | $6.72 | ||
| Q3 25 | $0.81 | $1.65 | ||
| Q2 25 | $0.70 | $1.50 | ||
| Q1 25 | $1.17 | $1.37 | ||
| Q4 24 | $0.74 | $1.39 | ||
| Q3 24 | $0.66 | $1.30 | ||
| Q2 24 | $0.74 | $1.10 | ||
| Q1 24 | — | $1.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $363.4M | $132.8M |
| Total DebtLower is stronger | $1.2B | — |
| Stockholders' EquityBook value | $911.5M | $938.4M |
| Total Assets | $2.5B | $8.7B |
| Debt / EquityLower = less leverage | 1.34× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $363.4M | $132.8M | ||
| Q3 25 | $296.4M | $193.5M | ||
| Q2 25 | $292.9M | $212.6M | ||
| Q1 25 | $306.8M | $193.1M | ||
| Q4 24 | $320.8M | $134.4M | ||
| Q3 24 | $299.3M | $132.3M | ||
| Q2 24 | $344.4M | $70.9M | ||
| Q1 24 | — | $57.1M |
| Q4 25 | $1.2B | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $1.2B | — | ||
| Q1 25 | $1.2B | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $911.5M | $938.4M | ||
| Q3 25 | $849.2M | $788.8M | ||
| Q2 25 | $882.3M | $761.8M | ||
| Q1 25 | $820.8M | $741.4M | ||
| Q4 24 | $906.9M | $713.4M | ||
| Q3 24 | $878.9M | $719.9M | ||
| Q2 24 | $905.4M | $674.6M | ||
| Q1 24 | — | $667.9M |
| Q4 25 | $2.5B | $8.7B | ||
| Q3 25 | $2.4B | $8.5B | ||
| Q2 25 | $2.5B | $8.4B | ||
| Q1 25 | $2.5B | $8.2B | ||
| Q4 24 | $2.5B | $8.1B | ||
| Q3 24 | $2.5B | $8.0B | ||
| Q2 24 | $2.5B | $7.9B | ||
| Q1 24 | — | $7.8B |
| Q4 25 | 1.34× | — | ||
| Q3 25 | 1.44× | — | ||
| Q2 25 | 1.39× | — | ||
| Q1 25 | 1.49× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $93.6M | $38.9M |
| Free Cash FlowOCF − Capex | $87.2M | $31.9M |
| FCF MarginFCF / Revenue | 25.7% | 16.4% |
| Capex IntensityCapex / Revenue | 1.9% | 3.6% |
| Cash ConversionOCF / Net Profit | 2.09× | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | $308.1M | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $93.6M | $38.9M | ||
| Q3 25 | $111.3M | $34.9M | ||
| Q2 25 | $17.4M | $18.9M | ||
| Q1 25 | $116.6M | $22.2M | ||
| Q4 24 | $43.8M | $95.0M | ||
| Q3 24 | $48.8M | $21.2M | ||
| Q2 24 | $-27.4M | $27.3M | ||
| Q1 24 | — | $23.2M |
| Q4 25 | $87.2M | $31.9M | ||
| Q3 25 | $106.3M | $33.9M | ||
| Q2 25 | $13.6M | $18.3M | ||
| Q1 25 | $100.9M | $20.9M | ||
| Q4 24 | $35.2M | $88.8M | ||
| Q3 24 | $39.4M | $18.9M | ||
| Q2 24 | $-33.1M | $26.3M | ||
| Q1 24 | — | $21.9M |
| Q4 25 | 25.7% | 16.4% | ||
| Q3 25 | 32.5% | 38.8% | ||
| Q2 25 | 4.2% | 22.1% | ||
| Q1 25 | 30.5% | 25.5% | ||
| Q4 24 | 10.1% | 115.1% | ||
| Q3 24 | 11.4% | 24.7% | ||
| Q2 24 | -9.8% | 36.2% | ||
| Q1 24 | — | 30.0% |
| Q4 25 | 1.9% | 3.6% | ||
| Q3 25 | 1.5% | 1.1% | ||
| Q2 25 | 1.2% | 0.8% | ||
| Q1 25 | 4.7% | 1.7% | ||
| Q4 24 | 2.5% | 8.1% | ||
| Q3 24 | 2.7% | 2.9% | ||
| Q2 24 | 1.7% | 1.3% | ||
| Q1 24 | — | 1.9% |
| Q4 25 | 2.09× | 0.40× | ||
| Q3 25 | 2.88× | 1.47× | ||
| Q2 25 | 0.51× | 0.88× | ||
| Q1 25 | 2.01× | 1.13× | ||
| Q4 24 | 1.17× | 4.82× | ||
| Q3 24 | 1.44× | 1.14× | ||
| Q2 24 | -0.71× | 1.74× | ||
| Q1 24 | — | 1.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HAE
| Hospital | $143.5M | 42% |
| Plasma Productsand Services | $138.9M | 41% |
| Blood Center Productsand Services | $56.6M | 17% |
TMP
Segment breakdown not available.
